{"id":"triptorelin-pamoate-pr-3-month","safety":{"commonSideEffects":[{"rate":"50-70%","effect":"Hot flashes"},{"rate":"10-20%","effect":"Injection site reaction"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This decrease in sex hormone production is achieved through continuous stimulation of the GnRH receptors in the pituitary gland, resulting in a downregulation of GnRH receptors and a decrease in the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). As a result, sex hormone production is reduced, leading to a decrease in testosterone levels.","oneSentence":"Triptorelin Pamoate PR 3-month is a gonadotropin-releasing hormone (GnRH) agonist that works by mimicking the action of the natural hormone GnRH, leading to a decrease in sex hormone production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:12.262Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer"},{"name":"Premature puberty"}]},"trialDetails":[{"nctId":"NCT03232281","phase":"PHASE3","title":"Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis","status":"COMPLETED","sponsor":"Ipsen","startDate":"2017-07-28","conditions":"Endometriosis","enrollment":300},{"nctId":"NCT01160315","phase":"PHASE2, PHASE3","title":"Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure","status":"COMPLETED","sponsor":"Erasme University Hospital","startDate":"2002-07","conditions":"Fertility Preservation, Alkylating Agents, Lymphoma","enrollment":118}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Triptorelin pamoate for injection 15 mg"],"phase":"phase_3","status":"active","brandName":"Triptorelin Pamoate PR 3-month","genericName":"Triptorelin Pamoate PR 3-month","companyName":"Ipsen","companyId":"ipsen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Triptorelin Pamoate PR 3-month is a gonadotropin-releasing hormone receptor agonist used to prevent chemotherapy-induced ovarian failure. It is indicated for conditions such as fertility preservation, lymphoma, and endometriosis, and is administered as a 3-month depot formulation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}